Cancer9-a | Liposome Formulation9-b | Dose | Schedule | Total Responses | Complete Response | Response Duration |
---|---|---|---|---|---|---|
mg/m2 | % | days | ||||
Kaposi's sarcoma (n = 16)9-e | Doxil | 20 | ×3 wk | 75 | 98 | |
Kaposi's sarcoma (n = 24)9-f(patients failed standard chemotherapy) | DaunoXome | 40 | ×2 wk | 54.2 | 8.3 | 84 |
Kaposi's sarcoma (n = 22)9-g | DaunoXome | 50–60 | ×2 wk | 55 | 5 | |
Kaposi's sarcoma (n = 34)9-h | Doxil | 20 | ×3 wk | 73.5 | 5.8 | 63 |
Kaposi's sarcoma (n = 29)9-i | Free DOX | 20 | ×2 wk | 48 | 3 | 105 |
Kaposi's sarcoma (n = 116)9-j | DaunoXome | 40 | ×2 wk | 25 | 2.5 | 175 |
ABV | 10, 15 U, 1 mg | ×2 wk | 28 | 0.9 | 168 | |
Kaposi's sarcoma (n = 30)9-k | DaunoXome | 40 | ×2 wk | 73 | 153 | |
Kaposi's sarcoma (n = 29)9-l | DaunoXome | 40 | ×2 wk | 45 | 70 | |
Kaposi's sarcoma (n = 53)9-m(patients failed standard chemotherapy) | Doxil | 20 | ×3 wk | 36 | 1.8 | 128 |
Ovarian carcinoma (n = 35)9-c 9-n | Doxil | 40–50 | ×3 wk | 25.7 | 2.9 | 180 |
Metastatic breast carcinoma (n = 64)9-o | Doxil | 45–60 | 3–4 wk | 31 | 6.3 | 270 |
Kaposi's sarcoma (n = 40)9-p | Doxil | 20 | ×3 wk | 70 | ||
Kaposi's sarcoma (n = 121)9-q | Doxil | 20 | ×3 wk | 58.7 | 5.8 | 160.4 |
BV | 15 IU/m2, 2 mg | ×3 wk | 23.3 | 0.8 | 156.7 | |
Kaposi's sarcoma (n = 133)9-r | Doxil | 20 | ×2 wk | 45.9 | 0.8 | 90 |
ABV | 20, 10, 1 mg | ×2 wk | 24.8 | 92 | ||
Metastatic breast carcinoma (n = 69)9-s | TLC D-99 | 75 | ×3 wk | 33 | 3 | |
Free DOX | 75 | ×3 wk | 28 | 1 | ||
Metastatic breast carcinoma (n = 69)9-t | TLC D-99/CPA/5-FU9-e | 60, 500, 500 | ×3 wk9-d | 68 | 5 |
CPA, cyclophosphamide; 5-FU, 5-fluorouracil.
↵9-a Values are number of accessable patients.
↵9-b The composition, size, and drug/lipid ratio for DaunoXome and Doxil are listed in Table 1.
↵9-c Patients failed to respond to platinum- and paclitaxel-based regimens.
↵9-d Both CPA and TLC D-99 were administered on day 1, and 5-FU was administered on days 1 and 8.
↵9-e Simpson et al. (1993).
↵9-f Presant et al. (1993).
↵9-g Gill et al. (1995).
↵9-h Harrison et al. (1995).
↵9-i Gill et al. (1991).
↵9-j Gill et al. (1996).
↵9-k Girard et al. (1996).
↵9-l Uthayakumar et al. (1996).
↵9-m Northfelt et al. (1997).
↵9-n Muggia et al. (1997).
↵9-o Ranson et al. (1997).
↵9-p Amantea et al. (1997).
↵9-q Stewart et al. (1998).
↵9-r Northfelt et al. (1998).
↵9-s Harris et al. (1998).
↵9-t Valero et al. (1999).